EdiGene Completed 81.5 Million Yuan Pre-B2 Round of Financing

According to VCBeat, on September 17, 2019, EdiGene Inc.(EdiGene), a biotechnology company of gene editing, announced the successful completion of 81.5 million yuan Pre-B2 round of financing. This round of investment was invested by IDG Capital and Lilly Asia Ventures.

Meanwhile, EdiGene also announced a new R&D collaboration with a clinical-stage biopharmaceutical company, which is dedicated to developing innovative T-cell therapies, to expand allogeneic T-cell therapies. The details of the cooperation were not disclosed.

Founded in 2015 by genome editing professor Wei Wensheng, EdiGene is a biotechnology company specializing in genome editing technology. The company carries the mission to translate the cutting-edge genome editing technologies into novel therapeutics for genetic diseases and cancer, and creative solutions to advance drug discovery. EdiGene is currently developing gene-editing therapies including beta-thalassemia gene-editing therapy, blood tumor gene-editing therapy, etc. 

In 2018, EdiGene was awarded as one of the ten biotech companies selected by Nature Biotechnology as representing "some of the best (and most richly financed) science that was commercialized from academia". 

In 2019, EdiGene was selected as one of the 50 Most Innovative Companies in China by FAST Company. 

Founded in 1992, IDG Capital is a leading investment firm, focused on developing extraordinary companies through our expertise in private equity and venture capital, as well as real estate. The company works with private equity and venture capital fund managers, investment advisors and business entities around the world. 

Lilly Asian Ventures makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical company. The company mainly invests in promising life science companies with strong management teams and innovative technology and/or business models. Its initial focus is primarily on opportunities in China, although it will take the investments in the east and south Asia into account.